Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.22
-0.14-5.93%
At close: Aug 14, 5:00 PM EST
$2.26
0.04231.91%
After Hours: Aug 14, 7:22 PM EST
Protalix BioTherapeutics Inc Analyst Ratings
PLXAMEX
Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open
Conference Call: The most recent conference call started at 8:00 AM, 4 days agoClick to view the webcast
Consensus Rating1
Buy
Highest Price Target1
$12.00
Lowest Price Target1
$12.00
Consensus Price Target1
$12.00
Protalix BioTherapeutics Analyst Ratings and Price Targets | AMEX:PLX | Benzinga
Protalix BioTherapeutics Inc has a consensus price target of $12 based on the ratings of 1 analysts. The high is $12 issued by HC Wainwright & Co. on March 19, 2026. The low is $12 issued by HC Wainwright & Co. on March 19, 2026. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on March 19, 2026, November 21, 2025, and February 3, 2025, respectively. With an average price target of $13 between HC Wainwright & Co., there's an implied 474.64% upside for Protalix BioTherapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Protalix BioTherapeutics
FAQ
What is the target price for Protalix BioTherapeutics (PLX) stock?
The latest price target for Protalix BioTherapeutics (AMEX:PLX) was reported by HC Wainwright & Co. on March 19, 2026. The analyst firm set a price target for $12.00 expecting PLX to rise to within 12 months (a possible 430.43% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protalix BioTherapeutics (PLX)?
The latest analyst rating for Protalix BioTherapeutics (AMEX:PLX) was provided by HC Wainwright & Co., and Protalix BioTherapeutics reiterated their buy rating.
When was the last upgrade for Protalix BioTherapeutics (PLX)?
There is no last upgrade for Protalix BioTherapeutics
When was the last downgrade for Protalix BioTherapeutics (PLX)?
There is no last downgrade for Protalix BioTherapeutics.
When is the next analyst rating going to be posted or updated for Protalix BioTherapeutics (PLX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protalix BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protalix BioTherapeutics was filed on March 19, 2026 so you should expect the next rating to be made available sometime around March 19, 2027.
Is the Analyst Rating Protalix BioTherapeutics (PLX) correct?
While ratings are subjective and will change, the latest Protalix BioTherapeutics (PLX) rating was a reiterated with a price target of $12.00 to $12.00. The current price Protalix BioTherapeutics (PLX) is trading at is $2.26, which is out of the analyst’s predicted range.
